Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback